Ponatinib
Leukemia, Myeloid, Accelerated-Phase
Explore 12 assets in Leukemia, Myeloid, Accelerated-Phase →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Incyte Biosciences International Sàrl
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03934372CT.gov Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Leukemia, Myeloid, Accelerated-Phase
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ponatinib (this asset) | Incyte Biosciences International Sàrl | P1/2 | CCC · 48 |
| Fludarabine | University of Illinois at Chicago | P2 | BBB |
| Cyclophosphamide | University of Illinois at Chicago | P2 | BBB |
| Cyclosporin A | University of Michigan Rogel Cancer Center | P2 | BBB |
| Tacrolimus | University of Michigan Rogel Cancer Center | P2 | BB |
| Nivestim | Roswell Park Cancer Institute | P2 | BB |
| Methotrexate | University of Michigan Rogel Cancer Center | P2 | BB |
| Busulfanum | University of Illinois at Chicago | P2 | BB |
| Dasatinib | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | P3 | B |
+38 more in the Leukemia, Myeloid, Accelerated-Phase cohort
Other indications for Ponatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Myeloid Leukemia | — | P2 | BB · 66 |
| B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) | — | P3 | BB · 65 |
| Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | — | P2 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ponatinib in Leukemia, Myeloid, Accelerated-Phase. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ponatinib-leukemia-myeloid-accelerated-phase
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →